NeuroMed Technologies (Vancouver, BC)

CMDF Investment: $4,592,000.00
Focus: Central Nervous System Disorders   Cardiovascular Diseases & Blood Products  
www.neuromedtech.com

Neuromed Technologies is a private biopharmaceutical company committed to developing the next generation of chronic pain drugs. It is the only company in the world with a sole focus on target-specific calcium channel drugs. Launched in 1998; Neuromed has strong financial backing; outstanding research and development staff and a lead candidate in clinical trials. The company's proprietary methodology and advanced electrophysiological screening systems give them a competitive advantage in drug discovery. Neuromed's pipeline programs are designed around validated clinical targets associated with large; unmet markets including pain; anxiety; epilepsy and cardiovascular diseases. The company's lead chronic pain drug candidate is the first orally available selective N-type calcium channel blocker to be tested in clinical trials. Neuromed's drugs are aimed at large markets currently underserved due to either a lack of suitably effective therapeutics or by drugs fraught with considerable side effects